Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

被引：43

作者：

Hepburn, MJ ^{[1
]}

Kortepeter, MG ^{[1
]}

Pittman, PR ^{[1
]}

Boudreau, EF ^{[1
]}

Mangiafico, JA ^{[1
]}

Buck, PA ^{[1
]}

Norris, SL ^{[1
]}

Anderson, EL ^{[1
]}

机构：

[1] USA, Div Med, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA

来源：

VACCINE | 2006年 / 24卷 / 15期

关键词：

yellow fever vaccine; booster; neutralizing antibody;

D O I：

10.1016/j.vaccine.2005.12.055

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1,1: 10: Group 2, 1:20-1:40 and Group 3, > 1:40. The percent with >= four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/12 1, Group 2) and 10% (8/79, Group 3) (p < 0.0001). The median times to titer failure (< 1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p < 0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination. Published by Elsevier Ltd.

引用

页码：2843 / 2849

页数：7

共 32 条

[11] PERSISTENCE OF MEASLES ANTIBODY AFTER REVACCINATION [J].

MARKOWITZ, LE ;

ALBRECHT, P ;

ORENSTEIN, WA ;

LETT, SM ;

PUGLIESE, TJ ;

FARRELL, D .

JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (01) :205-208

[12] Advanced age a risk factor for illness temporally associated with yellow fever vaccination [J].

Martin, M ;

Weld, LH ;

Tsai, TF ;

Mootrey, GT ;

Chen, RT ;

Niu, M ;

Cetron, MS .

EMERGING INFECTIOUS DISEASES, 2001, 7 (06) :945-951

[13]

McClain DJ, 2000, J MED VIROL, V60, P77, DOI 10.1002/(SICI)1096-9071(200001)60:1&lt

[14]

77::AID-JMV13&gt

[15]

3.0.CO

[16]

2-S

[17] LIMITATIONS OF THE COMPLEMENT-FIXATION TEST FOR DISTINGUISHING NATURALLY ACQUIRED FROM VACCINE-INDUCED YELLOW-FEVER INFECTION IN FLAVIVIRUS-HYPERENDEMIC AREAS [J].

MONATH, TP ;

CRAVEN, RB ;

MUTH, DJ ;

TRAUTT, CJ ;

CALISHER, CH ;

FITZGERALD, SA .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1980, 29 (04) :624-634

[18] Comparative safety and immunogenicity of two yellow fever 17D vaccines (Arilvax and YF-VAX) in a Phase III multicenter, double-blind clinical trial [J].

Monath, TP ;

Nichols, R ;

Archambault, WT ;

Moore, L ;

Marchesani, R ;

Tian, J ;

Shope, RE ;

Thomas, N ;

Schrader, R ;

Furby, D ;

Bedford, P .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2002, 66 (05) :533-541

[19] Prevention of yellow fever in persons traveling to the tropics [J].

Monath, TP ;

Cetron, MS .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (10) :1369-1378

[20] Clinical proof of principle for ChimeriVax™:: recombinant live, attenuated vaccines against flavivirus infections [J].

Monath, TP ;

McCarthy, K ;

Bedford, P ;

Johnson, CT ;

Nichols, R ;

Yoksan, S ;

Marchesani, R ;

Knauber, M ;

Wells, KH ;

Arroyo, J ;

Guirakhoo, F .

VACCINE, 2002, 20 (7-8) :1004-1018

← 1 2 3 4 →